This document explains the main differences between two sets of performance metrics:
|
|
|
- Meryl Henry
- 9 years ago
- Views:
Transcription
1 Document Version 2.0 Date November 2013 The (70 day benchmark) and the NIHR Clinical Research Network High Level Objectives: a description of purpose, definition and differences Introduction This document explains the main differences between two sets of performance metrics: 1. The exercise, relating to the 70-day benchmark and delivery of trials to time and to target by individual providers of NHS Services which have entered into a contract with NIHR since Autumn 2011; and, 2. The NIHR Clinical Research Network (CRN) High Level Objectives (HLOs) which relate to the initiation and delivery of clinical research studies included on the NIHR CRN Portfolio. What are the metrics and why have they been introduced? The Government wishes to see a dramatic and sustained improvement in the performance of providers of NHS services in initiating and delivering clinical research. The Performance in Initiating and metrics, announced in the Government s Plan for Growth 1, require providers of NHS services to submit performance data on a 70-day benchmark to recruit first patients into clinical trials. They also include the Performance in Delivery exercise, which measures delivery of commercial contract trials to time and target so the incentive for trusts to set up studies quickly is balanced with an incentive that trusts will not do so without proper feasibility and then fail to deliver. Submission by providers of NHS services 2 of data on their performance against these benchmarks has been a condition of all new NIHR contracts since autumn The exercise encourage accountability for performance in the initiation and delivery of clinical trials within individual providers of NHS services. What are the? The are the CRN s agreed performance objectives for CRN activity. The High Level Objectives include targets to increase the proportion of studies in the NIHR CRN Portfolio that deliver to their planned recruitment time and target, to reduce the time taken to achieve NHS permission through the Coordinated System for gaining NHS Permission (CSP), and to reduce the time taken to recruit first participants into NIHR CRN Portfolio studies. They were introduced in April The CRN High Level Objectives encourage improved performance across whole clinical research studies, which are likely to be taking place across several providers of NHS services NIHR Metrics Comparison v2.0 November 2013 Page 1 of 5
2 Do the exercise and the share the same aims? Yes, both sets of performance metrics share the same overall aims, which are to increase the number of patients able to participate in research and enhance the nation s attractiveness as a host for research. The two sets of metrics complement each other: the NIHR Performance in Initiating and encourages accountability within individual providers of NHS services, while the CRN High Level Objectives encourage improved performance across whole studies. However, there are several key differences between them which are outlined below. What are the main differences between the and the CRN High Level Objectives? The focus of the is within individual providers of NHS services. The focus of the is on the performance of entire clinical research studies included on the NIHR CRN Portfolio. Further important differences between the two sets of metrics: 1) Inclusive research 2) Two separate data collections Data is collected for clinical trials only 3 ; as described in the first four definitions of question 2 of the IRAS Filter, regardless of funder or inclusion in the NIHR Portfolio. Apply to all studies that are processed through the NIHR CRN systems and apply to all types of research that are eligible for CRN support and included in the NIHR Portfolio, not just Clinical Trials of an Investigational Medicinal Products (CTIMPs). Submitted directly from NHS Provider to the NIHR Central Commissioning Facility (CCF) on a quarterly basis, via the Clinical Trials Performance Submission Platform. Performance data on the HLOs are collected on an ongoing basis via the NIHR CRN information systems. 3) Comparing and contrasting the Delivering Clinical Research and 40 and 30 day High Level Objective Targets: Measurements start points, clock-stopping and end points Measurements a) The Performance in Initiating (70-day) benchmark is a single measure taken from the date of receipt of Valid Research Application 3 to the date of First Patient Recruitment. Measures performance at an individual provider of NHS Services. Data collection does include time taken to gain NHS Permission, but this does not constitute a separate benchmark. b) Measuring performance at individual providers of NHS services. 3 NIHR Metrics Comparison v2.0 November 2013 Page 2 of 5
3 Start-points a) Include two separate targets: firstly, a median target of 40 days for the time taken for an NIHR CRN study to achieve NHS Permission at all sites; secondly, a target of 30 days for time taken to recruit a first patient in to an NIHR CRN study once Permission has been issued. b) Measuring performance across a whole study. For CSP studies, the start point metric is the date of receipt of Valid Research Application (Site Specific Information and associated documents) for local review. For non-csp studies, the start point is the receipt of an entire Valid Research Application package, as described on the associated IRAS Checklist. The start point of the HLO4 metric, relating to the median time taken across all sites to achieve NHS Permission though CSP is the receipt of the Valid R&D Submission. The CRN s High Level Objective 4, reduce the time taken to achieve NHS permission through CSP for NIHR studies, captures all applications received through CSP, which also includes BRC, BRU and CLAHRC studies. Eligibility of research studies for inclusion on the NIHR CRN portfolio and thus access to CSP are defined at Clock-stopping End-points There is no clock-stopping for NIHR Performance in Initiating and. The NIHR understands that, especially at the beginning of the exercise, there will be a number of reasons why the Performance in Initiating (70-day) benchmark is not met. Providers of NHS services are therefore asked to provide explanation as to the nature of delays to initiation of clinical trials that do not meet the benchmark. The include clockstops, as these objectives aim to exclude factors that are completely outside the CRN s remit; for example the time from NHS permission to first Network Site Initiation Visit for commercial contract studies. For the 70-day benchmark, the end point is the date of First Patient Recruitment. The date of First Patient Recruitment means the date that the first patient (or legal representative) provided informed consent, as recorded on the associated informed consent form. The High Level Objective relating to the recruitment of the first patient is measuring performance across a whole study, so the end point of the metric is the date that the first patient is recruited to the whole study, across all sites. The date of first patient recruitment means the date that the first patient consented to the study. 4) for Delivering Clinical Research and Recruitment to Time and Target for The initial focus is on commercial contract clinical trials. The NIHR CCF collects performance data from providers of NHS services on recruitment to time and target for every NIHR Metrics Comparison v2.0 November 2013 Page 3 of 5
4 5) Excluded research commercial contract clinical trial which the provider has hosted within the previous 12 months. The NIHR CRN collects performance data on recruitment to time and target for all commercial contract and noncommercial studies in the NIHR CRN Portfolio which started on or after April 1 st 2010 (HLO2). Data is not collected for any studies other than clinical trials, as described in the first four definitions of question 2 of the IRAS Filter. Certain studies are excluded from the measurement, with the aim of eliminating factors completely outside the control of the NIHR CRN. For example, commercial contract studies which are terminated by the sponsor for safety issues. Can data collected also be used for reporting to the NIHR CCF on the Delivering Clinical Research? The and the NIHR CRN High Level Objectives measure separate aspects of clinical research, however some of the data points may overlap. It is important to note that the only apply to Portfolio studies which are processed through CSP and therefore the data collected for these measures is not comprehensive enough to provide the full dataset required for the NIHR Performance in Initiating and data which covers both Portfolio and Non-Portfolio studies. When collating returns to CCF, providers of NHS services can use relevant NIHR CRN High Level Objective data points for those studies processed through CSP to contribute to the data submission for calculation of the NIHR Performance in Initiating (70-day) benchmark: for example, the time to complete local processes and issue permission. Dates for the first patient recruited at individual sites for studies on the NIHR CRN Portfolio are not currently collected in national NIHR CRN information systems to enable use by providers of NHS services. This is because the Delivering Clinical Research metrics are currently collected by CCF on an individual provider of NHS services basis, whereas the CRN HLOs are recorded in CRN information systems on a whole study basis. Where are the Data and the NIHR CRN High level objectives published? The data is published by each provider of NHS services with a relevant NIHR Contract on their own website. There is a minimal data set which must be published at the end of each quarter. The latest list of providers of NHS services can be accessed via the NIHR website at: The CRN High Level Objectives are published in quarterly performance reports written by the Clinical Research Network and can be accessed via the Coordinating Centre Website at: NIHR Metrics Comparison v2.0 November 2013 Page 4 of 5
5 Figure 1: Differences between the NIHR Performance in Initiating (70-day) benchmark and the CRN High Level Objectives. 00 Performance in Initiating (70-day) benchmark Receipt of Valid Research Application NHS Permission from providers of NHS services recruited at site Trial recruitment closes NIHR CRN High Level Objectives Day 0 HLO #4: 40 days (Median) Receipt of valid R&D submission for study Day 0 NHS Permission at all sites (median) Day 40 HLO #5: 30 days First Network site NHS Permission or Site Initiation Visit Day 40 recruited into study NIHR Metrics Comparison v2.0 November 2013 Page 5 of 5 HLO #2: Study specific recruitment target in planned recruitment period recruited into study Trial recruitment closes time and target met? Day X
National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP)
National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP) Operating Manual Please check the CRN Website for the latest version. Version: 6.0 Status: Consultation in
Attributing the costs of health and social care Research & Development (AcoRD)
Frequently Asked Questions Annex B Q1. Why have you revised the guidance on attributing Research Costs, Support Costs and Treatments Cost in the NHS? A. The definitions of Research Costs, NHS Support Costs
Summary of the role and operation of NHS Research Management Offices in England
Summary of the role and operation of NHS Research Management Offices in England The purpose of this document is to clearly explain, at the operational level, the activities undertaken by NHS R&D Offices
An introduction to Research Management and Governance (RM&G) in the NHS
An introduction to Research Management and Governance (RM&G) in the NHS Rachel Davis Assistant RM&G Project Manager Natassia Embury R&D Facilitator 14/04/2014 Delivering clinical research to make patients,
Attributing the costs of health and social care Research & Development (AcoRD)
Frequently Asked Questions Updated December 2015 Annex B Contents 1. Introduction... 2 2. Funding sources... 2 3. Clinical Research Network funding... 5 4. Application advice services/nhs permissions...
Q1. Why have you revised the guidance on attributing Research Costs, Support Costs and Treatments Cost in the NHS?
Annex B Frequently Asked Questions Updated May 2015 Q1. Why have you revised the guidance on attributing Research Costs, Support Costs and Treatments Cost in the NHS? A. The definitions of Research Costs,
Document Title: Research Database Application (ReDA)
Document Title: Research Database Application (ReDA) Document Number: SOP035 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
Trust/Host Site Approval. Presented by: Anika Kadchha Research Governance Officer
Trust/Host Site Approval Presented by: Anika Kadchha Research Governance Officer Joint Research & Enterprise Office Training 19 th January Outline What is Research NHS Ethics (if required) Host Site Approval
The Health Research Authority. Janet Wisely. April 2015
The Health Research Authority Janet Wisely April 2015 The HRA as an organisation A Non-Departmental Public Body January 2015 Public sector employees on NHS terms Volunteer members of committees A Special
CLINICAL RESEARCH NETWORK
CLINICAL RESEARCH NETWORK Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
CRN: South London Funding Model
Summary of Partnership Group Agreement to Clinical Research Network: South London Funding Model Proposal 1. Introduction The Clinical Research Network: South London (CRN: South London) was formed in April
Document Title: Trust Approval and Research Governance
Document Title: Trust Approval and Research Governance Document Number: SOP034 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
Research funding applications involving Cardiff & Vale UHB. Emma Lewis R&D Coordinator. Cardiff and Vale UHB Bwrdd lechyd Prifysgol Caerdydd a r Fro
Research funding applications involving Cardiff & Vale UHB Emma Lewis R&D Coordinator Objectives R&D review of grant applications Identifying resources required for your project Attributing costs using
NIHR Guideline B01 Research & Development Operational Capability Statement V 5 2015-16 Updated March 20145
NIHR Guideline B01 Research & Development Operational Capability Statement V 5 2015-16 Updated March 20145 Version History Version number Valid from Valid to Date approved Approved by Updated by RDOCS
INCOME DISTRIBUTION FROM NIHR ADOPTED INDUSTRY SPONSORED STUDIES
Title: Outcome Statement: INCOME DISTRIBUTION FROM NIHR ADOPTED INDUSTRY SPONSORED STUDIES To ensure that income distribution from work undertaken within the Trust for National Institute for Health (NIHR)-adopted
Archiving of Research Documentation
Suspension, Termination & Completion Standard Operating Procedure VERSION / REVISION: 2.0 EFFECTIVE DATE: 28 05 12 REVIEW DATE: 28 05 14 AUTHOR(S): CONTROLLER: APPROVED BY: Clinical Trials Manager; Recruitment
Study-wide considerations: identifies the areas of the criterion the lead reviewer should consider when conducting the review
UK STUDY-WIDE GOVERNANCE CRITERIA FOR R&D REVIEW INTRODUCTION The following document is intended to provide operational guidance to the person taking the UK lead in conducting the R&D Study-Wide review
NIHR Clinical Research Network Learning Management System (LMS)
NIHR Clinical Research Network Learning Management System (LMS) The LMS is an online system to enable researchers undertaking NIHR portfolio related research to access a variety of online and taught courses.
gsop-32-02 - Vendor Assessment SOP page 1 of 10
gsop-32-02 - Vendor Assessment SOP page 1 of 10 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust VENDOR ASSESSMENT Research & Development
University Hospital Southampton NHS Foundation Trust
University Hospital Southampton NHS Foundation Trust EDGE was developed within the National Cancer Research Network in 2000 as an information system solution to help front line clinical research staff
NORWICH CLINICAL TRIALS UNIT OVERVIEW
NORWICH CLINICAL TRIALS UNIT OVERVIEW This document provides an overview of the Norwich Clinical Trials Unit. Sections 1 to 3 describe the Norwich Clinical Trials Unit remit and structure. Section 4 gives
OxB01 v1.00. R&D Operational Capability Statement
OxB01 v1.00 R&D Operational Capability Statement Version History Version number Valid from Valid to Date approved Approved by Updated by OxB01 v1.00 03/03/2011 02/03/2013 03/03/2011 Board of Directors
Proportionate Review (PR) IRAS Application & Documents. Authorisations & Signatures. Contact CBS Team
Proportionate Review (PR) What is Proportionate Review? Is my study suitable for Proportionate Review? IRAS Application & Documents What is an IRAS application form? What documents do I need? Completing
Document Title: Project Management of Papworth Sponsored Studies
Document Title: Project Management of Papworth Sponsored Studies Document Number: SOP009 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G
Dorset Research Consortium. Research Governance: A handbook for Researchers in Dorset
Dorset Research Consortium Research Governance: A handbook for Researchers in Dorset DRC Version 1 dated 25 th July 2012 Research Governance: The Basics... 4 What is Research Governance?... 4 The Research
NIHR Research Design Service London Dr Peter Lovell Deputy Director
NIHR Research Design Service London Dr Peter Lovell Deputy Director Research Design Service (RDS) A national network of support services; Supporting those who are putting together REGIONAL RDS North East
Adopting Site Quality Management to Optimize Risk-Based Monitoring
Adopting Site Quality Management to Optimize Risk-Based Monitoring Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective
Appendix 3 INDIVIDUAL PATIENT DRUG TREATMENT. POLICY AND PROCESS FOR DECISION MAKING September 2007
Appendix 3 INDIVIDUAL PATIENT DRUG TREATMENT POLICY AND PROCESS FOR DECISION MAKING September 2007 Approved by Board: 6 th September 2007 Date Implemented: 1 st October 2007 Review Date: September 2008
RESEARCH AND DEVELOPMENT GAINING NHS RESEARCH PERMISSION FROM CARDIFF AND VALE UHB - GUIDANCE FOR RESEARCHERS. Research Governance Group
RESEARCH AND DEVELOPMENT GAINING NHS RESEARCH PERMISSION FROM CARDIFF AND VALE UHB - GUIDANCE FOR RESEARCHERS Reference No: UHB 074 Version No: 5 Previous Trust / LHB Ref No: N/A Documents to read alongside
RESEARCH TRAINING & CAREER DEVELOPMENT
RESEARCH TRAINING & CAREER DEVELOPMENT Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets
STANDARD OPERATING PROCEDURE. Risk Assessment of STH sponsored CTIMPs
Research Department STANDARD OPERATING PROCEDURE of STH sponsored CTIMPs SOP History None SOP Number C118 Created STH Research Department (EW) Reviewed STH Research Department (EW) Superseded Version 1.0,
Trial Delivery SOP 05 Trial Archiving
Gloucestershire Research and Development Consortium Standard Operating Procedure R&D SOP TD 05Trial Archiving Trial Delivery SOP 05 Trial Archiving IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO
The Royal Wolverhampton NHS Trust
The Royal Wolverhampton NHS Trust Trust Board Report Meeting Date: 23 rd February 2015 Title: National Institute for Health Research Clinical Research Network: West Midlands Annual Plan submission 2015-16
Policy Flowchart. Policy Title: Research Governance, Conduct and Management Policy. Reference and Version No: IG6 Version 5
Policy Title: Research Governance, Conduct and Management Policy Reference and Version No: IG6 Version 5 Author and Job Title: J Greenaway Research and Development Manager Executive Lead Medical Director
Research Study Close-down and Archiving Procedures
Title: Outcome Statement: Research Study Close-down and Archiving Procedures To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
EHR4CR ENABLING PROACTIVE RESEARCH
EHR4CR ENABLING PROACTIVE RESEARCH Neelam Patel Neelam Consulting Electronic Health Records for Clinical Research 76 Why change how I currently operate? To more visible to the clinical trial community
Marie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager
Standard Operating Procedures (SOP) for: Monitoring SOP 28 Version 7.0 Number: Number: Effective Date: 29 th November 2015 Review Date: 6 th January 2017 Author: Reviewer: Reviewer: Authorisation: Name
COMPLAINTS FROM RESEARCH SUBJECTS ABOUT UCL SPONSORED STUDIES AND TRIALS
COMPLAINTS FROM RESEARCH SUBJECTS ABOUT UCL SPONSORED STUDIES AND TRIALS Dr Susan Kerrison Clinical Research Support Office [email protected] Services 1 of 8 COMPLAINTS FROM RESEARCH SUBJECTS ABOUT
Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL
Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
Principles for Responsible Clinical Trial Data Sharing
Principles for Responsible Clinical Trial Data Sharing Our Commitment to Patients and Researchers Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical
Executive Summary and Recommendations: National Audit of Learning Disabilities Feasibility Study
Executive Summary and Recommendations: National Audit of Learning Disabilities Feasibility Study Contents page Executive Summary 1 Rationale and potential impact of a future audit 2 Recommendations Standards
ECONOMIC FOOTPRINT OF CTs IN BELGIUM STRATEGIC PLAN TO PROMOTE CTs
ECONOMIC FOOTPRINT OF CTs IN BELGIUM STRATEGIC PLAN TO PROMOTE CTs Ingrid Maes Director Pharma, Healthcare and Life Sciences PwC on behalf of: PwC on behalf of: PwC on behalf of: PwC PwC on behalf of:
Hyperion Asset Management Limited Brokerage Allocations (Soft Dollar Dealing) and Adviser Commission Policy
Hyperion Asset Limited Brokerage Allocations (Soft Dollar Dealing) and Adviser Commission Policy Document Control Owner Relates to Date Last Updated Version Primary Rules/Rationale Managing Director, Hyperion
A Guide to Efficient Trial Management. Trials Managers Network
A Guide to Efficient Trial Management Trials Managers Network The Fourth Edition (2014) of the Guide to Efficient Trial Management was produced by an appointed Editorial Board and a dedicated group of
Canadian Cancer Clinical Trials Network Request for Application 2015 Network Affiliated Cancer Centre. Submission Guidelines
Canadian Cancer Clinical Trials Network Request for Application 2015 Network Affiliated Cancer Centre Submission Guidelines Lead Organization Announcement Type Purpose Eligibility Available Funding Canadian
CENTRAL MANCHESTER UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
CENTRAL MANCHESTER UNIVERSITY HOSPITALS NHS FOUNDATION TRUST Agenda Item 9.3 Report of: Paper prepared by: Robert Pearson Medical Director, CMFT Lisa Miles Senior Project Manager, Research & Innovation
Recognition of Prior Learning (RPL) Kit. BSB50607 Diploma of Human Resources Management
Recognition of Prior Learning (RPL) Kit BSB50607 Diploma of Human Resources Management Applicant: Date: Diploma of Human Resources Management RPL Kit 1 Applicant declaration: I have completed the following
Medicines for Human Use (Clinical Trials Regulations) 2004. Informed consent in clinical trials
Medicines for Human Use (Clinical Trials Regulations) 2004 Informed consent in clinical trials Introduction 1. This information note summarises the statutory requirements for informed consent of participants
The new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
Wales Patient Access Scheme: Process Guidance
Wales Patient Access Scheme: Process Guidance July 2012 (Updated September 2014) This guidance document has been prepared by the Patient Access Scheme Wales Group, with support from the All Wales Therapeutics
North East London Cancer Research Network. Annual Report
North East London Cancer Research Network Annual Report Financial Year 2012-2013 1 The National Institute for Health Research Cancer Research Network (formerly National Cancer Research Network) was created
New Beginnings. Nonprofit Incubator Guidelines
New Beginnings Nonprofit Incubator New Beginnings Nonprofit Incubator Guidelines Resources for Human Development (RHD) operates The New Beginnings Nonprofit Incubator to nurture, equip and grow nonprofit
Frequently Asked Questions Special Handling Labor Certification
Frequently Asked Questions Special Handling Labor Certification What is the Labor Certification Process? The labor certification process is the first step of a three stage process to obtain permanent residence
DATA MANAGEMENT IN CLINICAL TRIALS: GUIDELINES FOR RESEARCHERS
Reference Number: UHB 139 Version Number: 2 Date of Next Review: 14 Apr 2018 Previous Trust/LHB Reference Number: N/A DATA MANAGEMENT IN CLINICAL TRIALS: GUIDELINES FOR RESEARCHERS Introduction and Aim
Research & Development Guidance for Students
Research & Development Guidance for Students 2 Contents Introduction 3 Understanding the Research Approval Process 3 Is My Project Audit, Research or Something Else 4 What Next? 4 R&D Step by step Guide
TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet
TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating
Introduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6
Index Index Section Page Introduction 2 1. The Role of Pharmacy Within a NHS Trust 3 2. Pharmacy Staff 4 3. Pharmacy Facilities 5 4. Pharmacy and Resources 6 5. Prescription Charges 7 6. Communication
Priority Program Translational Oncology Applicants' Guidelines
Stiftung Deutsche Krebshilfe Dr. h.c. Fritz Pleitgen Präsident Spendenkonto Kreissparkasse Köln IBAN DE65 3705 0299 0000 9191 91 BIC COKSDE33XXX Priority Program Translational Oncology Applicants' Guidelines
Improving Emergency Care in England
Improving Emergency Care in England REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 1075 Session 2003-2004: 13 October 2004 LONDON: The Stationery Office 11.25 Ordered by the House of Commons to be printed
The anatomy of a grant proposal
The anatomy of a grant proposal 1 st October 2015 / Lucy Parker, MaryCate MacLennan, Steff Hazlehurst Excellence in specialist and community healthcare The anatomy of a grant proposal 1st October 2015
Five Simple Steps to Increase Supplier Adoption of einvoicing Jeff White
Five Simple Steps to Increase Supplier Adoption of einvoicing Jeff White Director, Implementations & Integration ADP Procure-to-Pay Solutions Agenda Trends in invoice automation Barriers to einvoicing
Competency Framework for Non-Clinical Research Staff
Birmingham and the Black Country Comprehensive Local Research Network Greater Midlands Cancer Research Network Pan Birmingham Cancer Research Network Competency Framework for Non-Clinical Research Staff
CONTROLLED DOCUMENT- DO NOT COPY STANDARD OPERATING PROCEDURE. STH Investigator
Research Department STANDARD OPERATING PROCEDURE STH Investigator Archiving of Essential Documentation Generated During Clinical Research SOP Number A127 Version Number V1.3 Effective Date Author Zoe Whiteley
SUMMARY PLAN DESCRIPTION
SUMMARY PLAN DESCRIPTION January 2012 DEATH BENEFIT RETIREMENT BENEFIT DISABILITY BENEFIT WITHDRAWAL BENEFIT Introduction The IBEW District Ten NECA Individual Equity Retirement Plan (often referred to
An information platform that delivers clinical studies better, faster, safer and more cost effectively
An information platform that delivers clinical studies better, faster, safer and more cost effectively Powering Process & Performance Proactively manage study start-up and execution Risk profile new sites
TRIAL MASTER FILE- SPONSORED
gsop-06-04 - Management of TMF for ENHT/ WHHT Sponsored CTIMPs Page 1 of 16 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust TRIAL MASTER
